# Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis

> **NCT07193316** · — · COMPLETED · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 38 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cirrhosis

## Interventions

- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT07193316
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-27
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-09-25
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193316, "Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07193316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*